Literature DB >> 1283702

Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis.

R Bicknell1, A L Harris.   

Abstract

Progress in our understanding of tumour angiogenesis and an appreciation of the marked differences between quiescent and proliferating endothelium are revealing new strategies for anticancer therapy. This article outlines these strategies and critically assesses their chances of success.

Entities:  

Mesh：

Year:  1992        PMID： 1283702

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  17 in total

Review 1.  Therapeutic inhibition of angiogenesis.

Authors:  Hua-Tang Zhang; Roy Bicknell
Journal:  Mol Biotechnol       Date:  2003-10       Impact factor: 2.695

Review 2.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model.

Authors:  L Possati; D Campioni; F Sola; L Leone; L Ferrante; C Trabanelli; M Ciomei; M Montesi; R Rocchetti; S Talevi; S Bompadre; A Caputo; G Barbanti-Brodano; A Corallini
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

4.  Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.

Authors:  Angela Coxon; James Bready; Hosung Min; Stephen Kaufman; Juan Leal; Dongyin Yu; Tani Ann Lee; Ji-Rong Sun; Juan Estrada; Brad Bolon; James McCabe; Ling Wang; Karen Rex; Sean Caenepeel; Paul Hughes; David Cordover; Haejin Kim; Seog Joon Han; Mark L Michaels; Eric Hsu; Grant Shimamoto; Russell Cattley; Eunju Hurh; Linh Nguyen; Shao Xiong Wang; Anthony Ndifor; Isaac J Hayward; Beverly L Falcón; Donald M McDonald; Luke Li; Tom Boone; Richard Kendall; Robert Radinsky; Jonathan D Oliner
Journal:  Mol Cancer Ther       Date:  2010-10       Impact factor: 6.261

Review 5.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

Review 6.  Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Authors:  J P Crew; T S O'Brien; A L Harris
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

7.  Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.

Authors:  Shima Uneda; Hirofumi Toi; Tomoko Tsujie; Masanori Tsujie; Naoko Harada; Hilda Tsai; Ben K Seon
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

8.  Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Constantinos Simopoulos; Alexandros Polychronidis; Kevin C Gatter; Adrian L Harris; Michael I Koukourakis
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 9.  Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis.

Authors:  N S Brown; R Bicknell
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

Review 10.  Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis.

Authors:  W Kolch; G Martiny-Baron; A Kieser; D Marmé
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.